

Karel Pavelka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6856925/publications.pdf>

Version: 2024-02-01

222
papers

28,952
citations

34016

52
h-index

5663

162
g-index

236
all docs

236
docs citations

236
times ranked

28707
citing authors

#	ARTICLE	IF	CITATIONS
1	Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210816.	1.2	1
2	Photogrammetric Co-Processing of Thermal Infrared Images and RGB Images. <i>Sensors</i> , 2022, 22, 1655.	2.1	8
3	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. <i>Rheumatology International</i> , 2022, 42, 803-814.	1.5	3
4	European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. <i>Rheumatology</i> , 2022, 61, 3799-3807.	0.9	7
5	Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials. <i>Rheumatology International</i> , 2022, 42, 205-213.	1.5	0
6	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
7	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021, 48, 48-57.	1.0	7
8	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 1823-1831.	0.9	4
9	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , 2021, 60, 820-828.	0.9	41
10	Knud Rasmussen Glacier Status Analysis Based on Historical Data and Moving Detection Using RPAS. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 754.	1.3	5
11	Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , 2021, 23, 11.	1.6	5
12	OUP accepted manuscript. <i>Rheumatology</i> , 2021, , .	0.9	0
13	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , 2021, 11, 1.	1.6	9,439
14	Astronomical Investigation to Verify the Calendar Theory of the Nasca Lines. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1637.	1.3	0
15	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. <i>Scientific Reports</i> , 2021, 11, 4719.	1.6	7
16	Earthen Jewish Architecture of Southern Morocco: Documentation of Unfired Brick Synagogues and Mellahs in the Drâa-Tafilalet Region. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1712.	1.3	14
17	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. <i>Scientific Reports</i> , 2021, 11, 6063.	1.6	17
18	P127â€¦fTreating rheumatoid arthritis patients with moderate disease activity: an analysis of the upadacitinib SELECT Phase III randomised studies. <i>Rheumatology</i> , 2021, 60, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. <i>Rheumatology</i> , 2021, 60, 5060-5072.	0.9	6
20	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. <i>Arthritis Research and Therapy</i> , 2021, 23, 173.	1.6	8
21	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicines</i> , 2021, 9, 650.	1.4	5
22	Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. <i>Vnitřní Lekarství</i> , 2021, 67, 195-200.	0.1	1
23	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. <i>Scientific Reports</i> , 2021, 11, 11525.	1.6	10
24	Transformations in the Photogrammetric Co-Processing of Thermal Infrared Images and RGB Images. <i>Sensors</i> , 2021, 21, 5061.	2.1	1
25	Clinical effectiveness and safety of intra-articular injection of HYALGO in the management of knee osteoarthritis symptoms: A multicenter prospective study. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2021, 19, 75-80.	0.6	1
26	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. <i>Biomarkers in Medicine</i> , 2021, 15, 5-13.	0.6	3
27	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , 2021, 8, 1775-1787.	1.1	10
28	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. <i>Biomolecules</i> , 2021, 11, 4.	1.8	5
29	Creating a Material Spectral Library for Plaster and Mortar Material Determination. <i>Materials</i> , 2021, 14, 7030.	1.3	2
30	Prevalence and distribution of cartilage and bone damage at metacarpal head in healthy subjects. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1394-1401.	0.4	2
31	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 17-24.	1.6	19
32	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA. <i>Rheumatology</i> , 2020, 59, 1640-1650.	0.9	18
33	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 183-192.	1.4	5
34	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020, 6, e001211.	1.8	17
35	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	1.8	33
36	STRUCTURE FROM MOTION PROCESSING OF ANALOGUE IMAGES CAPTURED BY ROLLEI METRIC CAMERA, DIGITIZED WITH VARIOUS SCANNING RESOLUTION. <i>Acta Polytechnica</i> , 2020, 60, 288-302.	0.3	4

#	ARTICLE	IF	CITATIONS
37	P200 Characterisation of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators. <i>Rheumatology</i> , 2020, 59, .	0.9	0
38	An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. <i>Rheumatology</i> , 2020, 59, 3858-3868.	0.9	26
39	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14868 patients with spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 2455-2461.	0.9	7
40	Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. <i>ACR Open Rheumatology</i> , 2020, 2, 119-127.	0.9	30
41	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. <i>BMC Rheumatology</i> , 2020, 4, 13.	0.6	1
42	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020, 9, 1-15.	1.0	6
43	Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. <i>Scientific Reports</i> , 2019, 9, 11218.	1.6	15
44	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.5	58
45	Prevalence and distribution of cartilage damage at the metacarpal head level in rheumatoid arthritis and osteoarthritis: an ultrasound study. <i>Rheumatology</i> , 2019, 58, 1206-1213.	0.9	17
46	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. <i>Cytokine</i> , 2019, 116, 13-20.	1.4	17
47	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. <i>Rheumatology</i> , 2019, 58, 2221-2229.	0.9	11
48	Examples of different techniques for glaciers motion monitoring using InSAR and RPAS. <i>European Journal of Remote Sensing</i> , 2019, 52, 219-232.	1.7	8
49	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. <i>Rheumatology International</i> , 2019, 39, 1037-1043.	1.5	6
50	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019, 38, 2411-2421.	1.0	4
51	The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. <i>Arthritis Research and Therapy</i> , 2019, 21, 77.	1.6	55
52	Study of Erbil Al-Qala citadel time changes by comparison of historical and contemporary image data. <i>European Journal of Remote Sensing</i> , 2019, 52, 202-208.	1.7	6
53	An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 84.	1.6	30
54	Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. <i>BMJ Open</i> , 2019, 9, e024713.	0.8	9

#	ARTICLE	IF	CITATIONS
55	FRI0403â€¦HIGH BASELINE PATIENTâ€™S COMPARED WITH EVALUATORâ€™S GLOBAL ASSESSMENT IS ASSOCIATED WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS â€œ DATA FROM THE EUROSPA COLLABORATION. , 2019, , .		0
56	THU0373â€¦ACTIVE SACROILIITIS ON MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANTERIOR UVEITIS. , 2019, , .		0
57	FRI0404â€¦POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		1
58	AB0687â€¦EFFECTIVENESS OF SPECIALIZED AND INTENSIVE ADL TRAINING IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES â€œ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
59	THU0453â€¦PROGRESSION OF PAIN, NUMBER OF PAINFUL AND SWOLLEN JOINTS AND ULTRASOUND DETECTED CHANGES IN THE GROUP OF 133 PATIENTS WITH HAND OSTEOARTHRITIS OVER THREE YEARS. , 2019, , .		0
60	FRI0107â€¦THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY. , 2019, , .		0
61	THU0638â€¦CONSIDERATIONS FOR IMPROVING QUALITY OF CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES. , 2019, , .		0
62	OP0066â€¦EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS â€œ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
63	FRI0378â€¦DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? â€œ RESULTS FROM THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		3
64	THU0101â€¦TORQUE TENO VIRAL LOAD FOR MONITORING OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS. , 2019, , .		0
65	FRI0379â€¦LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. , 2019, , .		0
66	FRI0634â€¦STANDARD REFERENCE VALUES OF METACARPAL HEAD CARTILAGE THICKNESSMEASUREMENT BY ULTRASOUND IN HEALTHY SUBJECTS. , 2019, , .		0
67	THU0062â€¦THE DYSREGULATION OF NK CELLS AND NON-CLASSICAL AND CLASSICAL MONOCYTE SUBPOPULATIONS IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS. , 2019, , .		0
68	THU0383â€¦PREVALENCE OF SPONDYLOARTHRITIS IN FIRST DEGREE RELATIVES OF PATIENTS WITH ANKYLOSING SPONDYLITIS. , 2019, , .		0
69	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. RMD Open, 2019, 5, e000994.	1.8	22
70	Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1989380.	1.2	34
71	RPAS for documentation of Nazca aqueducts. European Journal of Remote Sensing, 2019, 52, 174-181.	1.7	7
72	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatology International, 2019, 39, 469-478.	1.5	23

#	ARTICLE	IF	CITATIONS
73	Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis. <i>Clinical Rheumatology</i> , 2019, 38, 173-179.	1.0	7
74	DOCUMENTATION OF VANISHING CULTURAL AND TECHNICAL HERITAGE. , 2019, , .		0
75	FROM PHOTOGRAMMETRICAL DOCUMENTATION TO VIRTUAL RECONSTRUCTION AND OBJECT REPLICATION. , 2019, , .		0
76	USING TERRESTIAL AND AERIAL PHOTOGRAMMETRY IN ARCHAEOLOGY. , 2019, , .		1
77	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 342-343.	0.4	8
78	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 338-339.	0.4	1
79	Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 358-366.	0.4	7
80	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. <i>Clinical Rheumatology</i> , 2018, 37, 2055-2062.	1.0	23
81	Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. <i>Clinical Rheumatology</i> , 2018, 37, 1417-1420.	1.0	1
82	Biomarkers of hand osteoarthritis. <i>Rheumatology International</i> , 2018, 38, 725-735.	1.5	14
83	Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis. <i>Patient</i> , 2018, 11, 329-340.	1.1	7
84	AUTOMATIC CLASSIFICATION OF POINT CLOUDS FOR HIGHWAY DOCUMENTATION. <i>Acta Polytechnica</i> , 2018, 58, 165.	0.3	12
85	High Resolution Drone Surveying of the Pista Geoglyph in Palpa, Peru. <i>Geosciences (Switzerland)</i> , 2018, 8, 479.	1.0	11
86	Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. <i>RMD Open</i> , 2018, 4, e000809.	1.8	17
87	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	2.2	82
88	Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 264.	0.8	20
89	Enthesal involvement in patients with systemic lupus erythematosus: an ultrasound study. <i>Rheumatology</i> , 2018, 57, 1822-1829.	0.9	26
90	Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1276-1282.	0.5	51

#	ARTICLE	IF	CITATIONS
91	Using of both hyperspectral aerial sensing and RPAS multispectral sensing for potential archaeological sites detection. , 2018, , .		1
92	USING SATELLITE IMAGES FOR DOCUMENTATION OF DAMAGES IN ALEPPO HISTORICAL CENTRE DURING CIVIL WAR. , 2018, , .		0
93	FROM DIGITAL PHOTOGRAPHY TO A VIRTUAL 3D. , 2018, , .		0
94	Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 203-211.	0.7	11
95	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. Journal of Rheumatology, 2017, 44, 162-169.	1.0	17
96	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. Arthritis Care and Research, 2017, 69, 1287-1296.	1.5	95
97	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.5	3,366
98	UAV remote sensing capability for precision agriculture, forestry and small natural reservation monitoring. Proceedings of SPIE, 2017, , .	0.8	4
99	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 79.	1.6	35
100	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Annals of the Rheumatic Diseases, 2017, 76, 1679-1687.	0.5	138
101	Maintenance of remission with combination etanerceptâ€“DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatology International, 2017, 37, 1469-1479.	1.5	16
102	Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONDroitin versus CElecoxib versus Placebo Trial (CONCEPT). Annals of the Rheumatic Diseases, 2017, 76, 1537-1543.	0.5	75
103	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Annals of the Rheumatic Diseases, 2017, 76, 869-877.	0.5	114
104	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the â€œpan-European registry collaboration for abatacept (PANABA). Clinical Rheumatology, 2017, 36, 773-779.	1.0	33
105	08.48â€“...Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
106	08.49â€“...Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients â€“ preliminary data from a single-centre controlled study. , 2017, , .		0
107	Functional non-synonymous variants of ABCG2 and gout risk. Rheumatology, 2017, 56, 1982-1992.	0.9	62
108	Treatment of atlanto-axial subluxation secondary to rheumatoid arthritis by short segment stabilization with polyaxial screws. Acta Neurochirurgica, 2017, 159, 1791-1801.	0.9	5

#	ARTICLE	IF	CITATIONS
109	02.37â€¦Il-37 is associated with increased atherogenesis rather than disease activity in patients with rheumatoid arthritis. , 2017, , .		0
110	The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis â€œ a cohort study. Arthritis Research and Therapy, 2017, 19, 5.	1.6	15
111	Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. Cytokine, 2017, 97, 187-192.	1.4	10
112	08.47â€¦Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0
113	02.39â€¦Clusterin is increased in idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
114	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. PLoS ONE, 2017, 12, e0185323.	1.1	30
115	A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis. BMC Musculoskeletal Disorders, 2017, 18, 2.	0.8	11
116	Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Research and Therapy, 2017, 19, 285.	1.6	161
117	02.30â€¦High levels of mir-451a differentiate patients with clinically suspect arthralgia from healthy controls. , 2017, , .		0
118	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE, 2017, 12, e0175207.	1.1	92
119	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE, 2017, 12, e0183420.	1.1	32
120	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1â€¦year: a propensity score-matched cohort study. Annals of the Rheumatic Diseases, 2016, 75, 96-102.	0.5	61
121	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Annals of the Rheumatic Diseases, 2016, 75, 170-177.	0.5	48
122	Hypotheses about geoglyphs at Nasca, Peru: new discoveries. Geoinformatics FCE CTU, 2016, 15, 85-97.	0.4	1
123	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Annals of the Rheumatic Diseases, 2016, 75, 1336-1342.	0.5	55
124	Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Research and Therapy, 2016, 18, 275.	1.6	40
125	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open, 2016, 2, e000228.	1.8	15
126	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology, 2016, 55, 1466-1476.	0.9	20

#	ARTICLE	IF	CITATIONS
127	Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 308.	0.8	19
128	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	1.6	37
129	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 124.	1.6	48
130	Diaceirin: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016, 33, 75-85.	1.3	116
131	An update on biomarkers in axial spondyloarthritis. <i>Autoimmunity Reviews</i> , 2016, 15, 501-509.	2.5	58
132	Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 230-236.	0.9	20
133	Novel dysfunctional variant in <i>ABCG2</i> as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. <i>Rheumatology</i> , 2016, 55, 191-194.	0.9	24
134	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. <i>PLoS ONE</i> , 2016, 11, e0165498.	1.1	14
135	Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-6.	1.4	34
136	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 252.	1.6	60
137	Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. <i>Cytokine</i> , 2015, 73, 36-43.	1.4	44
138	Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2015, 34, 563-571.	1.0	36
139	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology</i> , 2015, 54, kev260.	0.9	17
140	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. <i>Biomarkers</i> , 2015, 20, 47-51.	0.9	12
141	A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Journal of Rheumatology</i> , 2015, 42, 912-919.	1.0	64
142	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
143	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 176.	0.8	36
144	Hyperuricemia and gout due to deficiency of hypoxanthine-guanine phosphoribosyltransferase in female carriers: New insight to differential diagnosis. <i>Clinica Chimica Acta</i> , 2015, 440, 214-217.	0.5	14

#	ARTICLE	IF	CITATIONS
145	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0132674.	1.1	28
146	Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 562-568.	0.2	6
147	Decreased Circulating Visfatin Is Associated with Improved Disease Activity in Early Rheumatoid Arthritis: Data from the PERAC Cohort. PLoS ONE, 2014, 9, e103495.	1.1	25
148	Complex Analysis of Urate Transporters SLC2A9, SLC22A12 and Functional Characterization of Non-Synonymous Allelic Variants of GLUT9 in the Czech Population: No Evidence of Effect on Hyperuricemia and Gout. PLoS ONE, 2014, 9, e107902.	1.1	33
149	Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. Arthritis Research and Therapy, 2014, 16, 460.	1.6	11
150	Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. International Journal of Clinical Rheumatology, 2014, 9, 415-430.	0.3	2
151	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1898-1904.	0.5	165
152	Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskeletal Disorders, 2014, 15, 14.	0.8	44
153	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatology, 2014, 53, 1520-1526.	0.9	72
154	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, 73, 492-509.	0.5	1,688
155	The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis. BMC Musculoskeletal Disorders, 2014, 15, 51.	0.8	16
156	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet, The, 2014, 383, 321-332.	6.3	232
157	Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. BMC Research Notes, 2013, 6, 115.	0.6	25
158	Acute Effects of Glucocorticoids on Serum Markers of Osteoclasts, Osteoblasts, and Osteocytes. Calcified Tissue International, 2013, 92, 354-361.	1.5	68
159	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet, The, 2013, 381, 918-929.	6.3	311
160	Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF± therapy and discontinuation of glucocorticoids. Rheumatology International, 2013, 33, 2001-2007.	1.5	10
161	Changes in Structure and Symptoms in Knee Osteoarthritis and Prediction of Future Knee Replacement Over 8 Years. Calcified Tissue International, 2013, 93, 502-507.	1.5	15
162	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. Cytokine, 2013, 64, 441-447.	1.4	19

#	ARTICLE	IF	CITATIONS
163	Leflunomide in psoriatic arthritis: Results from a large European prospective observational study. <i>Arthritis Care and Research</i> , 2013, 65, 464-470.	1.5	64
164	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1125-1135.	0.5	1,033
165	Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. <i>Lancet</i> , The, 2013, 381, 1541-1550.	6.3	568
166	Induction of response with etanercept+methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. <i>Clinical Rheumatology</i> , 2013, 32, 1275-1281.	1.0	15
167	Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic—data from the ATTRA registry. <i>Clinical Rheumatology</i> , 2013, 32, 1451-1458.	1.0	18
168	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
169	Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1621-1627.	0.5	93
170	A7.3—Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A48.3-A49.	0.5	0
171	Hyperspectral approach to a non-invasive survey of cultural heritage objects. , 2013, , .		0
172	USE OF HISTORICAL IMAGES FOR OBJECT RECONSTRUCTION. , 2013, , .		2
173	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 374-377.	0.5	64
174	Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, 2113-2119.	1.4	107
175	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1950-1954.	0.5	91
176	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2012, 51, v12-v21.	0.9	16
177	Clinical Efficacy of Etanercept Versus Sulfasalazine in Ankylosing Spondylitis Subjects with Peripheral Joint Involvement. <i>Journal of Rheumatology</i> , 2012, 39, 836-840.	1.0	25
178	Biologic registries in rheumatology: Lessons learned and expectations for the future. <i>Autoimmunity Reviews</i> , 2012, 12, 329-336.	2.5	18
179	Hip Fracture Incidence from 1981 to 2009 in the Czech Republic as a Basis of the Country-Specific FRAX Model. <i>Calcified Tissue International</i> , 2012, 90, 365-372.	1.5	19
180	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2012, 31, 67-71.	1.0	18

#	ARTICLE	IF	CITATIONS
181	Pentosidine, an Advanced Glycation End-Product, May Reflect Clinical and Morphological Features of Hand Osteoarthritis. <i>Open Rheumatology Journal</i> , 2012, 6, 64-69.	0.1	6
182	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A13.2-A14.	0.5	2
183	Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1895-1904.	0.5	345
184	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1575-1580.	0.5	188
185	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R122.	1.6	69
186	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. <i>Cytokine</i> , 2011, 55, 116-121.	1.4	31
187	Adipokine profile is modulated in subcutaneous adipose tissue by TNF α inhibitors in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2054-2056.	0.5	9
188	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.5	394
189	Modulation of subcutaneous adipose tissue adipokines by TNF- α blockade therapy in patients with inflammatory arthritides. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A85-A85.	0.5	0
190	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.5	71
191	Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6-months treatment plus 2-months observation in patients with osteoarthritis of the knee. <i>Clinical Rheumatology</i> , 2010, 29, 659-670.	1.0	59
192	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
193	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1410-1411.	0.5	94
194	Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1590-1594.	0.9	40
195	Prospective new biological therapies for rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009, 9, 102-107.	2.5	119
196	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539
197	Self-reported compliance with osteoporosis medication—Qualitative aspects and correlates. <i>Maturitas</i> , 2008, 60, 223-229.	1.0	14
198	World Congress on Osteoarthritis (Osteoarthritis Research Society International). <i>Future Rheumatology</i> , 2007, 2, 129-132.	0.2	0

#	ARTICLE	IF	CITATIONS
199	Knowledge of osteoporosis correlated with hormone therapy use and health status. <i>Maturitas</i> , 2007, 56, 21-29.	1.0	16
200	Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: Putative involvement in the pathogenesis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 779-789.	6.7	91
201	Some principles of the development of a clinical database/national register of selected inflammatory rheumatic diseases in the Czech Republic. <i>International Journal of Medical Informatics</i> , 2006, 75, 216-223.	1.6	10
202	S100A4 (Mts1): Is there any relation to the pathogenesis of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2006, 5, 129-131.	2.5	30
203	The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. <i>Arthritis and Rheumatism</i> , 2006, 54, 26-37.	6.7	1,634
204	Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: Comment on the article by Brandt and Mazzuca. <i>Arthritis and Rheumatism</i> , 2006, 54, 2339-2341.	6.7	5
205	Adalimumab in the treatment of rheumatoid arthritis. <i>Aging Health</i> , 2006, 2, 533-545.	0.3	7
206	COL6A1, the Candidate Gene for Ossification of the Posterior Longitudinal Ligament, Is Associated With Diffuse Idiopathic Skeletal Hyperostosis in Japanese. <i>Spine</i> , 2005, 30, 2321-2324.	1.0	91
207	Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs?. <i>International Journal of Clinical Practice</i> , 2005, 58, 5-12.	0.8	14
208	Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study. <i>BMC Musculoskeletal Disorders</i> , 2005, 6, 31.	0.8	19
209	Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. <i>Current Medical Research and Opinion</i> , 2004, 20, 1967-1977.	0.9	19
210	Natural Selection and Population History in the Human Angiotensinogen Gene (AGT): 736 Complete AGT Sequences in Chromosomes from Around the World. <i>American Journal of Human Genetics</i> , 2004, 74, 898-916.	2.6	122
211	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. <i>Lancet</i> , The, 2004, 363, 675-681.	6.3	1,662
212	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. <i>Menopause</i> , 2004, 11, 138-143.	0.8	104
213	Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. <i>Clinica Chimica Acta</i> , 2003, 328, 59-69.	0.5	39
214	Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis. <i>Archives of Internal Medicine</i> , 2002, 162, 2113.	4.3	584
215	Oral therapy with proteolytic enzymes decreases excessive TGF- β 2 levels in human blood. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, S10-S15.	1.1	55
216	Comparaison des signes cliniques, radiographiques, biologiques et scintigraphiques dans l'arthrose \hat{A} rosive et non \hat{A} rosive de la main. RA \hat{A} sultats apr \hat{A} s deux ans de suivi. <i>Revue Du Rhumatisme (Edition) Tj ETQ</i> 000 0 rgBT /Overlock		

#	ARTICLE	IF	CITATIONS
217	Osteonecrosis. Best Practice and Research in Clinical Rheumatology, 2000, 14, 399-414.	1.4	26
218	Predictive map of Ixodes ricinus high-incidence habitats and a tick-borne encephalitis risk assessment using satellite data. Experimental and Applied Acarology, 1998, 22, 417-433.	0.7	70
219	Intraindividual Differences in Pain Relief and Functional Improvement in Osteoarthritis with Diclofenac or Tramadol. Clinical Drug Investigation, 1998, 16, 421-429.	1.1	31
220	Characterization of Monoclonal Antibodies Recognizing Different Fragments of Cartilage Oligomeric Matrix Protein in Human Body Fluids. Archives of Biochemistry and Biophysics, 1997, 341, 8-16.	1.4	46
221	Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. Osteoarthritis and Cartilage, 1995, 3, 15-23.	0.6	22
222	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. Clinical and Experimental Rheumatology, 0, , .	0.4	1